未登录

S

Scott P. Henry

ionis pharmaceuticals, inc.

H指数:42

被引数:5,554

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute neuronal inhibition response caused by phosphorothioate antisense oligonucleotides following local delivery to the central nervous system

磷硫酰化反义寡核苷酸经局部递送至中枢神经系统后引起的急性神经元抑制反应

Nucleic Acids Research

IF13.1

2026-01-012

PRE

Cellular immune changes during severe antisense oligonucleotide-associated thrombocytopenia in a nonhuman primate model

JOURNAL OF IMMUNOLOGY

IF3.4

2025-03-010

PRE

Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations

评估治疗性寡核苷酸的杂交依赖性脱靶风险: 最新行业建议

NUCLEIC ACID THERAPEUTICS

IF4.7

2025-02-010

PRE

Carcinogenicity assessment of inotersen in Tg.rasH2 mice and Sprague-Dawley rats: Implications for 2′-MOE antisense oligonucleotides

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2025-01-010

OAAI

A Combined Fertility and Developmental Toxicity Study with an Antisense Oligonucleotide Targeting Murine Apolipoprotein C-III mRNA in Mice

NUCLEIC ACID THERAPEUTICS

IF4.7

2024-12-010

PRE

Complement C3d/C4d Deposition on Platelets Correlates with 2'-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys

NUCLEIC ACID THERAPEUTICS

IF4.7

2023-06-012

PRE

Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2023-01-313

OAAI

Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells

NUCLEIC ACID THERAPEUTICS

IF4.7

2022-12-0111

PRE

Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Thought TLR9 in Human Burkitt Lymphoma B Bjab Cells

NUCLEIC ACID THERAPEUTICS

IF4.7

2022-12-0110

PRE

Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs

评估基于寡核苷酸的药物的免疫原性潜力

NUCLEIC ACID THERAPEUTICS

IF4.7

2022-10-017

PRE

Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-08-0714

OAAI

Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of Triantennary N-Acetyl Galactosamine-Conjugated and Unconjugated-Antisense Oligonucleotides

NUCLEIC ACID THERAPEUTICS

IF4.7

2021-08-0111

PRE

Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2′-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2021-04-018

OAAI

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

IF7.9

2021-02-118

OAAI

Immunogenicity Assessment of Inotersen, a 2′-O-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and Safety

NUCLEIC ACID THERAPEUTICS

IF4.7

2020-10-0114

PREAI

Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

NUCLEIC ACID THERAPEUTICS

IF4.7

2020-06-0124

OAAI

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia

NUCLEIC ACID THERAPEUTICS

IF4.7

2020-04-0124

PREAI

Impurity Qualification Toxicology Study for a 2′-O-Methoxyethyl-Modified Antisense Inhibitor in Mice

NUCLEIC ACID THERAPEUTICS

IF4.7

2020-02-010

PREAI

Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2019-05-3077

PREAI

Antisense therapy targeting complement factor B

靶向补体因子B的反义治疗

MOLECULAR IMMUNOLOGY

IF3

2018-10-010

PREAI